Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.

Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma.
复制标题

DOI:
10.1038/sj.bjc.6604715
复制
发表时间:
2008-11-04
影响因子:
8.8
通讯作者:
Fujii H
Fujii H
中科院分区:
医学1区
文献类型:
--
作者:
Mizukami Y;Kono K;Maruyama T;Watanabe M;Kawaguchi Y;Kamimura K;Fujii H

文献摘要

参考文献

被引文献

相似文献

由于在人白细胞抗原(HLA)I类分子的背景下的抗原肽被细胞毒性T淋巴细胞(CTL)识别,HLA I类分子的下调是肿瘤细胞可以逃避CTL介导的抗肿瘤免疫的原因之一。在这项研究中,我们调查了食管鳞状细胞癌(ESCC)(n=70)及其转移灶(淋巴结(n=40)和肝脏(n=3))的HLA I类表达,免疫组化与抗HLA I类单克隆抗体(EMR 8 -5)。结果,43%的ESCC原发灶中HLA I类表达下调,90%的转移淋巴结中HLA I类表达下调。此外,原发肿瘤中HLA I类分子表达保留的患者与HLA I类分子表达下调的患者相比,生存率更高(P<0.01)。考克斯比例风险模型多因素分析显示,原发灶HLA I类表达下调是独立的预后不良因素(P<0.01)。总之,HLA-I类表达的下调经常发生在原发性肿瘤,并在更大程度上,在转移性病变的食管鳞癌患者,并与患者的生存率。
As antigenic peptides in the context of human leukocyte antigen (HLA) class I molecules are recognised by cytotoxic T lymphocytes (CTL), the downregulation of HLA class I molecules is one of the reasons why tumour cells can evade CTL-mediated anti-tumour immunity. In this study, we investigated HLA class I expression in oesophageal squamous cell carcinoma (ESCC) (n=70) and in their metastatic lesions (lymph nodes (n=40) and liver (n=3)), by immunohistochemistry with anti-HLA class I monoclonal antibody (EMR8-5). As a result, the downregulation of HLA class I expression in primary lesions of ESCC was observed in 43%, and that in metastatic lymph nodes was noted in 90%. Furthermore, patients with preserved HLA class I expression in primary tumours showed a better survival in comparison to those with downregulated HLA class I molecules (P<0.01). Furthermore, multivariate analysis using Cox's proportional hazards model revealed that the downregulated expression of HLA class I in primary lesions was an independent, unfavourable prognostic factor (P<0.01). In conclusion, the downregulation of HLA class I expression frequently occurred in primary tumour and, to a greater extent, in metastatic lesions of patients with ESCC and was associated with patient survival.
DOI: 10.1007/s00262-007-0362-8
发表时间: 2008-02
影响因子: 5.8
作者:
Mehta, Akash M.;Jordanova, Ekaterina S.;Kenter, Gemma G.;Ferrone, Soldano;Fleuren, Gert-Jan
通讯作者: Fleuren, Gert-Jan
DOI: 10.1084/jem.194.6.833
发表时间: 2001-09-17
期刊: The Journal of experimental medicine
影响因子: --
作者:
Tangri S;Ishioka GY;Huang X;Sidney J;Southwood S;Fikes J;Sette A
通讯作者: Sette A
DOI: 10.1007/s00262-005-0085-7
发表时间: 2006-08-01
影响因子: 5.8
作者:
Ramnath, N;Tan, D;Ferrone, S
通讯作者: Ferrone, S
DOI: 10.1007/s00262-008-0515-4
发表时间: 2008-11-01
影响因子: 5.8
作者:
Seliger, Barbara
通讯作者: Seliger, Barbara
DOI: 10.1093/carcin/22.10.1615
发表时间: 2001-10-01
期刊: CARCINOGENESIS
影响因子: 4.7
作者:
Nie, Y;Yang, GY;Yang, CS
通讯作者: Yang, CS